

# the **ADBL** report

Issue #98, September 2017

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross  
The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

#### EXPERT COMMITTEE MEMBERS:

Scott Klarenbach, MD, MSc (Health Econ), FRCPC (Chair)  
Saibal Nandy, MBBS, MRCPsych, FRCPC (Vice-Chair)  
Caitlin A. Clarke, BScPhm, PharmD  
Fiona Clement, PhD  
Glen J. Pearson, BScPhm, PharmD, FCSHP  
Cheryl A. Sadowski, BSc (Pharm), PharmD, FCSHP  
Jeremy Slobodan, BSP

#### ALBERTA HEALTH LIAISONS:

Chad Mitchell, BSc Pharm, MSc

#### ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Amanda Chung, BSc (Pharm)  
Sherry Dieleman, BSc (Pharm), MSc  
Connie Lussier, BSP, MA  
Darcia Wasarab-Rolland, BSc (Pharm)

## In this issue:

- *Brief Summary of Drug Review Activities*
- *Highlights of:*
  - ❖ *Products Originally Reviewed via the CDR*
  - ❖ *Drug Products added*
  - ❖ *Expedited IC Drug Products added*
  - ❖ *IC Drug Products added*
  - ❖ *Special Authorization Criteria changes*
  - ❖ *Restricted Benefit Criteria changes*

## *Brief Summary of Drug Review Activities*

The Expert Committee on Drug Evaluation and Therapeutics met on July 20, 2017. The Committee reviewed Manufacturer submissions for twenty (20) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of fifty-two (52) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, sixteen (16) Drug Products underwent Expedited Review for listing on the ADBL effective August 1, 2017, and four (4) Drug Products underwent Expedited Review for listing on the ADBL effective September 1, 2017.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at

<https://www.ab.bluecross.ca/dbl/publications.html>

## *Highlights of Products Originally Reviewed via the Common Drug Review (CDR)*

The following Drug Product was reviewed by CDR and the Expert Committee and added to the ADBL as a Restricted Benefit, effective August 1, 2017:

- **EYLEA\*** (aflibercept) (BAI) 2 mg/vial injection

The following Drug Products were reviewed by CDR and the Expert Committee and added to the ADBL via Special Authorization, effective September 1, 2017:

- **BRENZYS\*** (etanercept) (SSB) 50 mg/mL auto-injector syringe and injection syringe
- **ENTRESTO\*** (sacubitril/valsartan) (NOV) 24.3 mg/25.7 mg, 48.6 mg/51.4 mg & 97.2 mg/102.8 mg tablets

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

\*Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).\*

## ***Highlights of Drug Products Added***

The following Non-Interchangeable Old Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective September 1, 2017:

- **M-ESLON IR** (morphine sulfate) (ETP) **5 mg, 10 mg, 20 mg & 30 mg capsules**

## ***Highlights of Expedited Interchangeable (IC) Drug Products Added***

Addition of the following Expedited Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective September 1, 2017:

- **CASPOFUNGIN\*** (casposfungin) (MDA) **50 mg & 70 mg injections** listed via Restricted Benefit/SA
- **DEFERASIROX\*** (various brands: APX, TAR, TEV) **125 mg, 250 mg, & 500 mg dispersible tablets for oral suspension** listed via Step Therapy/SA

## ***Highlights of Interchangeable (IC) Drug Products Added***

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective September 1, 2017:

- **MINT-INDOMETHACIN** (indomethacin) (MPI) **25 mg & 50 mg capsules**

## ***Special Authorization Criteria Changes***

The Special Authorization criteria for coverage for the following Drug Products have been revised effective September 1, 2017, for the indication of chronic renal failure:

- **ARANESP\*** (darbepoetin) (AMG) **10 mcg /0.4 mL & 20 mcg /0.5 mL injection syringes, 100 mcg /mL, 200 mcg/ mL & 500 mcg/mL injections, 10 mcg/0.4 mL, 20 mcg /0.5 mL, 30 mcg /0.3 mL, 40 mcg/0.4 mL, 50 mcg /0.5 mL, 60 mcg/ 0.3 mL, 80 mcg/0.4 mL, 100 mcg/ 0.5 mL, 130 mcg/0.65 mL, 150 mcg/0.3 mL, 200 mcg/0.4 mL, 300 mcg/0.6 mL, 500 mcg/1.0 mL singleject prefilled injection syringes**
- **EPREX\*** (epoetin alfa) (JAI) **1,000 unit/0.5 mL, 2,000 unit/0.5 mL, 3,000 unit/0.3 mL, 4,000 unit/0.4 mL, 5,000 unit/0.5 mL, 6,000 unit/0.6 mL, 8,000 unit/0.8 mL, 10,000 unit/mL & 20,000 unit/0.5 mL injection syringes**

## ***Restricted Benefit Criteria Changes***

The Restricted Benefit criteria for coverage for the following Drug Product has been revised effective August 1, 2017 due to the addition of Eylea:

- **LUCENTIS\*** (ranibizumab) (NOV) **2.3 mg/vial injection**

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

\*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).\*